Publications by authors named "Thomas Relander"

Claim this Profile
S
Salvage therapy for Burkitt lymphoma with glofitamab: a case report.
Pedro Martins Almeida, Thomas Relander, Ola Linden

Leuk Lymphoma· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Not Available].
Elsa Lanke, Thomas Relander

Lakartidningen· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas.
Rahul S Bhansali, Fredrik Ellin, Thomas Relander, Miao Cao, Wenrui Li

Blood Adv· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(-like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group.
Ahmed Ludvigsen Al-Mashhadi, Henrik Cederleuf, Rasmus Kuhr Jensen, Torsten Holm Nielsen, Martin Bjerregård Pedersen, Thomas Relander

Am J Hematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients.
Monica Mead, Henrik Cederleuf, Maja Björklund, Xiaoyan Wang, Thomas Relander

Blood Adv· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identifying causal relationships of cancer treatment and long-term health effects among 5-year survivors of childhood cancer in Southern Sweden.
Anders Holst, Jan Ekman, Magnus Petersson-Ahrholt, Thomas Relander, Thomas Wiebe

Commun Med (Lond)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[New national treatment guidelines for primary cutaneous lymphoma].
Emma Belfrage, Thomas Relander, Hanna Brauner

Lakartidningen· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.
Gerald G Wulf, Bettina Altmann, Marita Ziepert, Francesco D'Amore, Gerhard Held, Thomas Relander

Leukemia· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas.
Fredrik Ellin, Matthew J Maurer, Line Srour, Umar Farooq, Mats Jerkeman, Thomas Relander

Br J Haematol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and Implementation of Survivorship Tools to Enable Medical Follow-Up After Childhood Cancer Treatment in Southern Sweden.
Magnus Petersson-Ahrholt, Thomas Wiebe, Lars Hjorth, Thomas Relander, Helena M Linge

JCO Clin Cancer Inform· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID).
Kristina Drott, Hans Hagberg, Karin Papworth, Thomas Relander, Mats Jerkeman

Blood Adv· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study.
Fredrik Ellin, Mats Jerkeman, Jenny Törnqvist, Lars Brudin, Thomas Relander

Hematol Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study.
Henrik Cederleuf, Lasse Hjort Jakobsen, Fredrik Ellin, Peter de Nully Brown, Thomas Stauffer Larsen, Thomas Relander

Leuk Lymphoma· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.
Matthew J Maurer, Fredrik Ellin, Line Srour, Mats Jerkeman, N Nora Bennani, Thomas Relander

J Clin Oncol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.
Henrik Cederleuf, Martin Bjerregård Pedersen, Mats Jerkeman, Thomas Relander, Francesco d'Amore

Br J Haematol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mycosis Fungoides: A Retrospective Study of 44 Swedish Cases.
Yvonne Eklund, Annika Aronsson, Artur Schmidtchen, Thomas Relander

Acta Derm Venereol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study.
Fredrik Ellin, Jenny Landström, Mats Jerkeman, Thomas Relander

Blood· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
Fredrik Ellin, Jenny Landström, Mats Jerkeman, Thomas Relander

Blood· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry.
Fredrik Ellin, Mats Jerkeman, Hans Hagberg, Thomas Relander

Acta Oncol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The histone deacetylase inhibitor valproic acid sensitizes diffuse large B-cell lymphoma cell lines to CHOP-induced cell death.
Malin Ageberg, Karin Rydström, Thomas Relander, Kristina Drott

Am J Transl Res· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
Francesco d'Amore, Thomas Relander, Grete F Lauritzsen, Esa Jantunen, Hans Hagberg

J Clin Oncol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estrogen receptor α single nucleotide polymorphism modifies the risk of azoospermia in childhood cancer survivors.
Patrik Romerius, Aleksander Giwercman, Christian Moëll, Thomas Relander, Eva Cavallin-Ståhl

Pharmacogenet Genomics· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis.
K-John J Cheung, Nathalie A Johnson, Joslynn G Affleck, Tesa Severson, Christian Steidl, Thomas Relander

Cancer Res· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
Francesco d'Amore, John Radford, Thomas Relander, Mats Jerkeman, Hervé Tilly

Br J Haematol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sperm DNA integrity in men treated for childhood cancer.
Patrik Romerius, Olof Ståhl, Christian Moëll, Thomas Relander, Eva Cavallin-Ståhl

Clin Cancer Res· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis